Objective-Atherosclerosis is a chronic autoimmune-like disease in which lipids and fibrous elements accumulate in the arterial blood vessels. T cells are present within atherosclerotic plaques, and their activation is partially dependent on costimulatory signals, which can either provide positive or negative signals that promote T-cell activation or limit T-cell responses, respectively. T-cell immunoglobulin and mucin domain 3 (Tim-3) is a coinhibitory type 1 transmembrane protein that affects the function of several immune cells involved in atherosclerosis, such as monocytes, macrophages, effector T cells, and regulatory T cells. In the present study, we determined the role of Tim-3 in the development of atherosclerosis. Approach and Results-Western-type diet-fed low-density lipoprotein receptor-deficient (LDLr −/− ) mice were treated with an anti-Tim-3 antibody for 3 and 8 weeks. Anti-Tim-3 administration increased fatty streak formation with 66% and increased atherosclerotic plaque formation after 8 weeks with 35% in the aortic root and with 50% in the aortic arch. Furthermore, blockade of Tim-3 signaling increased percentages of circulating monocytes with 33% and lesional macrophages with 20%. In addition, anti-Tim-3 administration increased CD4 + T cells with 17%, enhanced their activation status, and reduced percentages of regulatory T cells with 18% and regulatory B cells with 37%. 
C ostimulatory and coinhibitory molecules are important regulators of the immune system by fine-tuning innate and adaptive immune responses. Studies on atherosclerosis, a chronic inflammatory disease, 1 show that modulation of costimulatory and coinhibitory pathways affects its development by regulating T-cell responses. 2 Not only in secondary lymphoid tissues but also in the arterial wall, antigen-presenting cells, such as dendritic cells and macrophages, present antigens such as oxidized low-density lipoprotein (oxLDL) to T cells. The T cells can become either activated in the presence of costimulatory molecules or inhibited when T cells and antigen-presenting cells interact via coinhibitory molecules. Therefore, stimulating coinhibitory molecules may provide a novel therapeutic approach to prevent the activation or function of autoreactive immune cells in atherosclerosis. Previously, Gotsman et al 3 showed that the coinhibitory pathway PD-1/PD-L1/2 inhibits proatherogenic T-cell responses and atherosclerosis because PD-L1/2 −/− low-density lipoprotein receptor-deficient (LDLr −/− ) mice develop significantly larger atherosclerotic lesions compared with LDLr −/− mice. 3 T-cell immunoglobulin and mucin domain (Tim) proteins are type 1 transmembrane proteins expressed on various immune cells and are similar to PD-1/PD-L1/2 negative regulators of immune responses. Four functional TIM genes have been identified in the murine genome (TIM-1-4), whereas the human genome only contains 3 TIM genes (TIM-1, -3, and -4). 4 The genes encoding Tim proteins are located on chromosome 11 (mouse) and chromosome 5 (human), which are associated with enhanced susceptibility to allergy and several autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) and diabetes mellitus. 4 Tim-3 was first discovered as a specific marker for Th1 cells 5 but is also expressed on a variety of immune cells such as natural killer (NK) cells, monocytes, macrophages, and mast cells. 6 During innate immune responses, Tim-3 promotes inflammation via tumor necrosis factor-α (TNF-α) secretion by monocytes and antigen-presenting cells 7 and enhances macrophage clearance of intracellular pathogens. 8 However, in adaptive immune responses, Tim-3 terminates interferon-γ-driven inflammation by inducing cell death of T cells after binding to its ligand galectin-9, a soluble molecule that is upregulated by interferon-γ. 9 In addition, Tim-3 can induce regulatory T-cell (Treg) activity 10 and induce expansion of myeloid-derived suppressor cells, which play an important role in tumor immunology. 11 Recently, Zhang et al 12 showed that Tim-3 can also negatively regulate innate immune responses because reduced Tim-3 signaling by antibody blockade or knockdown with small interfering RNA increases the activation of monocytes.
The in vivo role of Tim-3 can be investigated using antiTim-3 antibodies, which interrupt the Tim-3-galectin-9 interactions. Previously, it was shown that blocking Tim-3 with either a Tim-3 blocking antibody or a Tim-3-Ig fusion protein enhances type 1 diabetes mellitus in nonobese diabetic mice and prevents the generation of immunologic tolerance in a transplantation model by dampening the function of Tregs. 13 Furthermore, in vivo administration of a Tim-3 blocking antibody enhances inflammation and demyelination in a mouse model of EAE by increasing the number and activation of macrophages. 5 Blockade of the Tim-3-galectin-9 interaction also accelerates graft-versus-host disease via enhanced activation of Th1 cells and cytotoxic T cells.
14 In addition, blocking Tim-3 signaling aggravates inflammatory heart disease in BALB/c mice by decreasing CD80 expression on macrophages and mast cells and by reducing Tregs. 15 Recently, Hou et al 16 showed that patients with atherosclerosis have augmented Tim-3 expression on NK cells, which might affect NK cell function during atherosclerosis. However, to date, the exact role of Tim-3 in atherosclerosis has not been investigated. In the present study, we therefore examined the role of Tim-3 during atherosclerosis development by treatment of LDLr −/− mice with a Tim-3 blocking antibody. This research provides novel information on the importance of the Tim-3 pathway in regulating immune responses and provides possibly new therapeutic targets to prevent atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

TIM-3 Is Upregulated During Atherosclerosis Development
To determine TIM-3 expression in atherosclerotic lesions, LDLr −/− mice were fed a Western-type diet, and slightly constrictive perivascular collars were placed around the carotid arteries, which leads to the development of shear stressinduced atherosclerotic lesions at the proximal site of the collars. As shown in Figure 1A , TIM-3 expression was elevated after placement of collars around carotid arteries of LDLr −/− mice fed a Western-type diet (P<0.05), with the highest induction 10 weeks after collar placement (52-fold increase, P<0.05). To investigate which circulating cell types express Tim-3 and upregulate Tim-3 during Western-type diet feeding, we determined Tim-3 expression on the surface of several immune cells of mice fed a Chow or Western-type diet for 8 weeks with flow cytometry (n=5 per group; Figure 1B ). In addition, we determined whether Tim-3 is upregulated on the cell surface of these immune cells during atherosclerosis induction. As shown in Figure I in the online-only Data Supplement, hypercholesterolemia did not affect the amount of Tim-3 expressed on each cell.
Blocking Tim-3 Signaling Aggravates Atherosclerosis
Because interference of the Tim-3 signaling pathway aggravates autoimmune diseases such as EAE, 5 mellitus, 13 and graft-versus-host disease 14 by dampening regulatory cells and enhancing monocyte and macrophage activation, we determined the role of Tim-3 in the initiation of atherosclerosis. We treated LDLr −/− mice twice a week with a Tim-3 blocking antibody (RMT3-23) and determined atherosclerotic lesion development after 3 and 8 weeks of Western-type diet feeding. Figure 2A and 2B shows representative cross-sections of lesions in the aortic valve area. Treatment with anti-Tim-3 significantly increased fatty streak formation in the aortic root with 66% (12.2±0.8×10 4 μm
2 ) compared with control mice (7.4±1.5×10 4 μm 2 ; P<0.05; Figure 2A ). After 8 weeks of Western-type diet feeding, a 35% increase in the aortic root lesion size was observed in anti-Tim-3-treated mice (5.2±0.5×10 5 μm 2 ) compared with control mice (3.8±0.2×10 5 μm 2 ; P<0.05; Figure 2B ). Previously, we showed that treatment with rat IgG, the isotype control for RMT3-23, did not alter atherosclerotic lesion size in comparison with PBS treatment. 17 During the experiment, anti-Tim-3 treatment did not affect body weight and total plasma cholesterol levels ( Figure IIA and IIB in the online-only Data Supplement). Furthermore, no differences were found in lesion extracellular matrix components (anti-Tim-3 mice: 11.1±1.5% and control mice: 12.1±1.8%; Figure 2C ). To check whether anti-Tim-3 treatment also affects atherosclerosis development at another site of the vasculature, we determined lesion size in the aortic arch. As shown in Figure 3 , anti-Tim-3 treatment (1.1±0.2×10 3 μm 2 ) aggravated atherosclerosis with 50% compared with control treatment (0.5±0.1×10 3 μm 2 ).
TIM-3 Blockade Enhances Circulating Monocytes and Lesional Macrophages
Monocytes play an important role in atherosclerosis development because monocytes migrate into the subendothelial space where they can differentiate into macrophages and eventually become foam cells. Previously, Tim-3 blockade has been associated with increased monocyte and macrophage activation and induces the expansion of macrophages.
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In our study, mice that received the Tim-3 antibody showed a 33% increase in circulating monocytes (control: 4.6±0.6% versus anti-Tim-3: 6.2±0.3%; P<0.01; Figure 4A ). In mice, 2 subsets of monocytes with distinct patterns of surface markers and behaviors during inflammation have been described: CD11b + Ly6G − Ly6C high monocytes and CD11b + Ly6G − Ly6C low monocytes. However, as shown in Figure IIIA and IIIB in the online-only Data Supplement, blockade of Tim-3 did not affect the frequency of these subsets. In line with increased circulating monocytes, lesional macrophage content was increased with 20% in anti-Tim-3-treated mice (49.0±2.3%) compared with control mice (40.7±2.9%; P<0.05; Figure 4B and 4C). An important key regulator of monocytes is monocyte chemotactic protein-1 (MCP-1), which enhances monocyte recruitment into the arterial wall. 18 As shown in Figure 4D , we did not observe differences in MCP-1 levels in serum of anti-Tim-3-treated and control-treated mice. However, oxLDL-stimulated macrophages exposed to anti-Tim-3 in vitro enhanced their secretion of MCP-1 in a dose-dependent manner ( Figure 4E ). Tim-3 can also induce a proinflammatory phenotype of macrophages independent from oxLDL because 50 µg/mL RMT3-23 significantly elevated MCP-1 secretion by macrophages ( Figure IIIC in the online-only Data Supplement). In addition, we extracted RNA from aortic arches of control mice and anti-Tim-3-treated mice and determined MCP-1 expression with quantitative polymerase chain reaction. In line with our in vitro data, a trend toward an ≈2-fold increase of MCP-1 expression was observed in atherosclerotic lesions of anti-Tim-3-treated mice compared with control mice ( Figure 4F ).
Because TNF-α production is also known to be regulated by the Tim-3 pathway, 7 we also determined the effect of Tim-3 blockade on TNF-α levels with ELISA. As shown in Figure IIID in the online-only Data Supplement, serum TNF-α levels did not differ between anti-Tim-3-treated mice and control mice, and although a trend toward increased TNF-α is observed in the supernatant of oxLDL-stimulated macrophages exposed to titrated amounts of the anti-Tim-3 antibody ( Figure IIIE in the online-only Data Supplement), these differences were not significant.
Anti-Tim-3 Treatment Reduces Apoptosis of Lymphocytes
Tim-3 expressed on macrophages and dendritic cells is also involved in phagocytosis of apoptotic cells by recognizing apoptotic cells through the loop between the F and G beta strands in the IgV domain. 19 In addition, Tim-3 can induce cell death of T cells. As shown in Figure 5A , we did not observe differences in lesion necrotic core content of anti-Tim-3 mice (24.5±2.7%) and control mice (28.7±2.5%). In addition, the percentage of apoptotic cells within the lesions did not significantly differ between anti-Tim-3 mice (0.70±0.21%) and control mice (0.80±0.18%, Figure 5B ). Interestingly, a lower percentage of splenic lymphocytes isolated from anti-Tim-3 mice (26.2±0.9%) underwent apoptosis than did control splenocytes (32.7±1.3%; P<0.01; Figure 5C ).
Reduced Tregs and Regulatory B Cells in Anti-Tim-3-Treated Mice
Several studies showed that interactions of Tim-3 with galectin-9 are essential for the generation of Tregs. 13, 20 Tregs play an important role in the regulation of T-cell-mediated immune responses through suppression of T-cell proliferation and cytokine production. Therefore, increased Treg numbers may be beneficial for patients with atherosclerosis. In accordance with literature, we observed an 18% reduction of circulating Tregs within the CD4 + T-cell population in antiTim-3-treated mice (8.8±0.2%) compared with control mice (10.8±0.6%; P<0.05; Figure 6A ) and a 17% reduction of Tregs in the spleen of anti-Tim-3-treated mice (5.8±0.3%) compared with control mice (7.0±0.4%; P<0.05; Figure 6A ). We also extracted RNA from atherosclerotic lesions in the aortic arches of control mice and anti-Tim-3-treated mice. As shown in Figure 6B , anti-Tim-3-treated mice showed a 70% reduction (P<0.001) in Foxp3 mRNA expression compared with control mice.
Another regulatory cell type is the regulatory B cell (Breg), which is an interleukin (IL)-10 producing B cell that induces Treg differentiation and inhibits proinflammatory cytokine production. 21 We observed a 37% decrease of splenic Bregs (CD5 Figure 6C ).
To determine whether anti-Tim-3 treatment affects the suppressive function of Tregs and Bregs, we isolated Tregs and Bregs and added titrated amounts to CD4 + T cells. Their suppressive capacity was determined with a Ki-67 staining or tritium thymidine incorporation, respectively. We also isolated RNA from the Tregs and analyzed relative mRNA expression of important molecules that are associated with Treg-mediated T-cell suppression: CTLA-4 and GITR. As shown in Figure IV in the online-only Data Supplement, interference in Tim-3 signaling does not affect the inhibitory function of Tregs and Bregs.
In addition, a 55% decrease in all IL-10-producing cells was measured in spleens of anti-Tim-3-treated mice (3.5±1.0%) compared with the control group (7.9±1.5%; P<0.05; Figure 6D ).
Tim-3 Blockade Increased the Percentage and Activation Status of CD4 + T Cells
Because Tregs control CD4 + T cells and Tim-3 blockade reduces Tregs, we determined the percentage of CD4 + T cells. As expected, we found significantly increased CD4 + T cells in the spleen of anti-Tim-3-treated mice (25.1±1.4%) compared with control mice (21.4±0.6%; P<0.05; Figure 6E ). VC and VD in the online-only Data Supplement, no large variances between the cytokine profiles of control (white bars) and anti-Tim-3 mice (black bars) were observed. The cytokines IL-13 and IL-17 were elevated in anti-Tim-3-treated mice (P<0.05). Anti-Tim-3-treated mice showed a large increase in serum IL-6, a proinflammatory/proatherogenic cytokine.
Anti-Tim-3 Induces a Proatherogenic B-Cell Profile
To assess the effect of Tim-3 blockade on humoral responses, we analyzed B1 and B2 cell subsets in the circulation, spleen, and peritoneum. As shown in Figure VI No differences in B-cell subsets were observed in blood and spleen. In addition, we determined oxLDL-specific antibodies in serum of anti-Tim-3-treated mice and control mice. Anti-Tim-3-treated mice showed elevated levels of IgM, IgG1, and IgG2b compared with control mice, which suggests that anti-Tim-3 treatment promotes the overall activation status of B cells.
Discussion
Acute cardiovascular syndromes are a major cause of death in Western society and are generally triggered by rupture of an atherosclerotic plaque. In atherosclerosis, an imbalance between pro-and anti-inflammatory T cells exists, with increased numbers of the first. Restoration of this balance by modulation of costimulatory and coinhibitory molecules may provide a very promising strategy to prevent cardiovascular disease. The role of coinhibitory Tim-3 has been established in several autoimmune diseases, such as EAE, graft-versushost disease, and type 1 diabetes mellitus; however, the contribution of Tim-3 to atherosclerosis development remains to be elucidated.
In the present study, we show that TIM-3 is expressed within the atherosclerotic lesion and increases during Western-type diet feeding. Furthermore, we found that Tim-3 was expressed on large populations of monocytes, dendritic cells, and NK cells, whereas only a few T cells, B cells, and neutrophils expressed Tim-3 on their surface. Previously, Hou et al 16 showed that patients with atherosclerosis have increased Tim-3 + NK cells compared with healthy controls. 16 In line with these findings, we observed that Western-type diet feeding increased not only the percentage of Tim-3 + NK cells, but also the percentage of Tim-3 + monocytes and Tim-3 + dendritic cells, cell types that largely contribute to the inflammatory process of atherosclerosis.
To investigate the contribution of Tim-3 to atherosclerosis development, we treated Western-type diet-fed LDLr −/− mice with an anti-Tim-3 antibody for 3 and 8 weeks. After 3 weeks of Western-type diet feeding, we observed already a significant 66% increase in the aortic root lesion size in antiTim-3-treated mice compared with control mice. Blockade of Tim-3 for 8 weeks increased atherosclerosis development with 35% in the aortic root and with 50% in the aortic arch compared with control treatment, independent of plasma cholesterol levels. These data illustrate that anti-Tim-3 treatment increased lesion development already from an early stage. Whereas there was no difference in lesion stability, lesions of anti-Tim-3-treated mice contained significantly more macrophages than lesions of control mice. In agreement, circulating monocytes were enhanced in anti-Tim-3 mice, and because monocytes migrate into the arterial wall and differentiate into macrophages that can take up oxLDL, this may result in enhanced lesional macrophages. To mimic foam cell responses in the lesion, we exposed oxLDL-loaded macrophages to anti-Tim-3 in vitro and showed that blockade of Tim-3 enhanced MCP-1 secretion, which may be responsible for increased monocyte infiltration and subsequent elevated lesional macrophages in anti-Tim-3-treated mice. In line with our in vitro data, treatment with anti-Tim-3 resulted in an ≈2-fold increase of MCP-1 expression in atherosclerotic lesions as compared with control mice, suggesting that MCP-1 may indeed be, at least partly, responsible for the increase in macrophage content. These data are in accordance with studies that show an essential role for Tim-3 in monocyte and macrophage function. Monney et al 5 appointed increased macrophage numbers and activation as the major cause of exacerbated EAE in mice treated with a blocking anti-Tim-3 antibody. Frisancho-Kiss et al 15 showed that anti-Tim-3 treatment during the innate response to viral infection in BALB/c mice increases macrophages and their activation in the heart, resulting in increased inflammatory heart disease, and Zhang et al 12 found that Tim-3 regulated pro-and anti-inflammatory cytokine expression in human CD14 + monocytes. Because Tim-3 signaling has previously been associated with apoptosis, we determined the percentage of apoptotic cells and necrotic core in lesions of anti-Tim-3 mice. In early lesions, apoptosis of macrophages limits lesion cellularity and suppresses lesion progression. However, in advanced stages, it induces necrotic core formation, which makes lesions susceptible for rupture. Therefore, it has to be taken into account that Tim-3 signaling could be beneficial in initial stages of atherosclerosis, but in later stages of atherosclerosis could promote plaque rupture. In our study, we do not observe differences in apoptosis or necrotic core content in the lesions of anti-Tim-3-treated mice and Tim-3 signaling also enhances Tregs, which have been shown to promote lesion stability in advanced stages of atherosclerosis. 22 More specifically, it has been reported that Tim-3-galectin-9 interaction promotes apoptosis of T cells. 9 We do see reduced apoptosis of lymphocytes in anti-Tim-3-treated mice, which in turn could be responsible for the increase in CD4 + T cells. Moreover, Tim-3 has also been implicated in regulating proinflammatory T-cell responses by promoting Treg function. Tregs dampen the immune response in atherosclerosis by secreting anti-inflammatory cytokines, such as IL-10, and by directly inhibiting effector T-cell proliferation. Seki et al 20 reported that Tim-3 activation by galectin-9 resulted in an induction of Tregs, and Frisancho-Kiss et al 15 showed that anti-Tim-3 administration reduces Treg populations in the heart during acute myocarditis. In addition, blockade of the Tim-3 pathway accelerated type 1 diabetes mellitus in nonobese diabetic mice in part by dampening Treg function.
In accordance with these findings, we also observed reduced Treg levels in spleen, blood, and atherosclerotic lesions after anti-Tim-3 administration, which contributed to the exacerbation of atherosclerosis. In addition, Bregs were significantly decreased with 37% in the spleen and with 44% in the peritoneum of anti-Tim-3-treated mice. The exact role of Bregs in atherosclerosis has not been clarified yet; however, Bregs secrete IL-10 and thereby inhibit secretion of proinflammatory cytokines and support Treg differentiation, which indicates a protective role for Bregs in atherosclerosis. The atheroprotective role of IL-10 has already been shown by Von Der Thüsen et al 23 who showed that IL-10 overexpression reduced atherosclerosis in LDLr −/− mice. Furthermore, adoptive transfer of Bregs inhibited the initiation of EAE in Bl6 mice immunized with MOG peptides, 24 and Mauri et al 25 demonstrated that a transfer of IL-10-producing B cells into DBA mice prevented rheumatoid arthritis development and ameliorated established arthritis. Finally, the percentage of IL-10-producing splenocytes was decreased with 55% after anti-Tim-3 treatment, which is in line with decreased Tregs and Bregs in anti-Tim-3 mice, which exert their function in part via IL-10 secretion. Notably, interference in Tim-3 signaling solely affects Tregs and Bregs by reducing their numbers because anti-Tim-3 treatment did not affect their inhibitory function.
Reduced Tregs promoted the percentage of total and activated peripheral CD4 + T cells in anti-Tim-3-treated mice. Whereas Th1, Th2, and Th17 cells were unaffected in the spleen and atherosclerotic lesions of anti-Tim-3-treated mice, CD4 + T cells of anti-Tim-3-treated mice produced more IL-17. This finding is in line with previous studies that showed that abrogation of the Tim-3 pathway induces IL-17 production. 26, 27 The role of IL-17 in atherosclerosis is controversial but mainly considered proatherogenic because the expression of IL-17 and RORγt is correlated to plaque size and exogenous IL-17 promotes the formation of atherosclerotic lesions in apolipoprotein E-deficient mice. 28 To study whether Tim-3 affects atherosclerosis through modulation of humoral immune responses, we determined B-cell subsets and oxLDL-specific antibody responses. AntiTim-3 treatment reduced the percentage of peritoneal B1 cells by 78%, whereas B2 cells were increased by 61%. B1 cells are considered antiatherogenic, 29 whereas B2 cells promote atherosclerotic lesion development, 30, 31 illustrating that antiTim-3 induces a proatherogenic B-cell profile. In addition, elevated levels oxLDL-specific antibodies were found in serum of anti-Tim-3-treated mice, which suggests that anti-Tim-3 treatment promotes the overall activation status of B cells.
In the present study, we are the first to provide direct evidence that the Tim-3 pathway is involved in the development of atherosclerosis. We show that Tim-3 acts as a negative regulator of atherosclerosis because blockade of Tim-3 augmented atherosclerotic lesion development, which was accompanied by increased circulating monocytes and lesional macrophages and by decreased Tregs and Bregs, which subsequently induced the activation of CD4 + T cells. In the future, the use of lymphocyte-deficient mice would be a very interesting approach to study the role of the adaptive immune system in anti-Tim-3-mediated aggravation of atherosclerosis. Moreover, approaches to promote the Tim-3 pathway, such as treatment with agonistic Tim-3 antibodies or galectin-9, may represent novel therapeutic strategies to inhibit atherosclerotic lesion development and prevent cardiovascular diseases. 
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